<DOC>
	<DOCNO>NCT00433368</DOCNO>
	<brief_summary>The purpose study determine whether L-Ornithine L-Aspartate effective improvement Overt Hepatic Encephalopathy .</brief_summary>
	<brief_title>Efficacy L-Ornithine-L-Aspartate Cirrhotics With Hepatic Encephalopathy</brief_title>
	<detailed_description>There effective treatment available hepatic encephalopathy moment ; therefore aim check efficacy safety L-ornithine L-aspartate ( LOLA ) . It provide critical substrate ureagenesis glutamine synthesis , two primary mechanism body rids excess ammonia . Ornithine specific activator ornithine carbamyl transferase carbamylphosphate synthetase , , addition , substrate ureagenesis . These reaction carry mainly periportal portion hepatic lobule . Aspartate ornithine , conversion alfa-ketoglutarate , substrates glutamine synthesis , perform exclusively small population perivenous hepatocytes , so-called perivenous scavenger cell . The ammonia lower effect result stimulation two basic mechanism ammonia detoxification study animal confirm human clinical trial .</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>N-Methylaspartate</mesh_term>
	<criteria>Cirrhosis , diagnose basis clinical finding , sonographic , and/or histologic basis , Patients &gt; 14 year , HE grade 1 4 accord West Haven Criteria , Hyperammonemia ( fast venous blood ammonia level &gt; 60 Âµmol/l ) , Patients single reversible precipitating factor HE constipation , hypokalemia , urinary tract infection , respiratory tract infection , spontaneous bacterial peritonitis ( SBP ) , dehydration , none . hepatocellular carcinoma , severe septicemia , active gastrointestinal bleeding , hepatorenal syndrome , acute superimpose liver injury , advance cardiac pulmonary disease end stage renal failure , patient minimal HE patient take sedative , antidepressant , benzodiazepine patient chronic HE metronidazole lactulose prior admission .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>L-ornithine-L-aspartate ,</keyword>
	<keyword>porto-systemic encephalopathy ,</keyword>
	<keyword>hepatic encephalopathy ,</keyword>
	<keyword>liver cirrhosis ,</keyword>
	<keyword>mental state</keyword>
</DOC>